Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArtivionAORT -2.71%81 EV-to-EBITDA is 22.64 as of Aug. 06, 2026, which is 41% below its 10-year median of 38.11. GuruFocus rates AORT with a GF Score™ of 81/100 and a GF Value™ of $28.51 (Fairly Valued). The stock has 5 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Artivion ranks worse than 71.68% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Artivion's enterprise value is $1,472.8 Mil.
Artivion's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $65.1 Mil. Therefore, Artivion's EV-to-EBITDA for today is 22.64.
The historical rank and industry rank for Artivion's EV-to-EBITDA or its related term are showing as below:
AORT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 18.48 Med: 38.11 Max: 162.23
Current: 22.64
During the past 13 years, the highest EV-to-EBITDA of Artivion was 162.23. The lowest was 18.48. And the median was 38.11.
AORT's EV-to-EBITDA is ranked worse than 71.68% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.485
vs AORT: 22.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Artivion's share price for today is $26.17.
Artivion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Artivion's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Artivion's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artivion EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Artivion's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Artivion's EV-to-EBITDA falls into.
Artivion's current Enterprise Value is $1,472.8 Mil.
Artivion's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $65.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artivion (AORT) has a EV-to-EBITDA of 22.64 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Artivion. This is 41% below median its historical median of 38.11. Over the past decade, Artivion's EV-to-EBITDA has ranged from 18.48 to 162.23. According to the industry distribution chart, Artivion ranks #367 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 71.7%.
Is Artivion's EV-to-EBITDA too high?
Artivion's current EV-to-EBITDA of 22.64 is 41% below median its 10-year median of 38.11. Over the past 10 years, this metric has ranged from a low of 18.48 to a high of 162.23. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.49. Artivion's value of 22.64 is 56.3% above this industry median. Based on the distribution chart, Artivion ranks #367 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Artivion has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Artivion's EV-to-EBITDA compare to IRMD and ATEC?
According to the Medical Devices & Instruments industry distribution chart, Artivion ranks #367 out of 512 companies for EV-to-EBITDA. This places Artivion in the lower half of its industry. The industry median EV-to-EBITDA is 14.49. Artivion's value of 22.64 is 56.3% above this benchmark. Historically, Artivion's own EV-to-EBITDA has ranged from 18.48 to 162.23 over the past decade. While the company's 10-year median is 38.11 vs. the industry median of 14.49, Artivion has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.49, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artivion's current EV-to-EBITDA of 22.64 is 56.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Artivion. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artivion's current EV-to-EBITDA is 22.64, which is 41% below median its own 10-year median of 38.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artivion stock overvalued right now?
Based on GuruFocus' analysis, Artivion (AORT) is currently considered Fairly Valued. The stock's GF Value™ is $28.51, compared to a current price of $26.17 — trading 8.2% below its estimated fair value. The current EV-to-EBITDA is 22.64, which is 41% below median its 10-year median of 38.11 and 56.3% above the Medical Devices & Instruments industry median of 14.49. Artivion's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Artivion (AORT), the current EV-to-EBITDA is 22.64 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Artivion (AORT) Overvalued in 2026?
Based on GuruFocus' analysis, Artivion stock appears to be undervalued.
The current stock price of $26.17 is trading 8.2% below its estimated GF Value™ of $28.51.
GuruFocus considers Artivion to be Fairly Valued.
Key valuation signals for AORT:
EV-to-EBITDA: 22.64 (41% below median its 10-year median of 38.11)
GF Value™: $28.51 vs. price of $26.17 (8.2% below fair value)
Industry Position: 56.3% above the Medical Devices & Instruments median (#367 of 512)
No single metric tells the full story. See the AORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
81GF Score
Get the complete analysis for AORT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AORT has been successfully added to your 
